ROTH Capital Partners Announces the Addition of Jerry Isaacson, Ph.D. to its Healthcare Research Team
ROTH Capital Partners (“ROTH”), www.roth.com, a full service investment bank focused on serving emerging growth companies and their investors, today announced that Jerry Isaacson, Ph.D. has joined the firm’s healthcare research team.
Dr. Isaacson is a Managing Director and Senior Research Analyst covering biotechnology and emerging therapeutics. Jerry has a broad range of experience covering companies in many different disease areas as well as medical devices and diagnostics. He is particularly focused on anti-infectives, gene therapy, and oncology. Prior to joining ROTH he spent seven years leading the research group of LifeSci Capital, where he built the research team from the ground up and initiated coverage on more than 100 companies. Prior to joining LifeSci Capital, Dr. Isaacson was an editor at the Medical Technology Stock Letter primarily covering oncology and diabetes companies. His previous experience includes work in the biotechnology industry, where he served in various roles ranging from analytical and medicinal chemistry to corporate communications and writing patents. Jerry earned his Ph.D. in organic chemistry at the University of California at San Diego conducting total synthesis of natural products and received his Bachelor of Arts degree in chemistry from Harvard University.
Jeff Martin, Director of Research, commented, “Building on our continued success in identifying compelling investment opportunities in the healthcare sector, I’m pleased to welcome Dr. Isaacson to our thought-leading biotechnology research team. His strong academic background in organic chemistry combined with his extensive experience in covering biotechnology companies will undoubtedly serve our clients well.”
Dr. Isaacson commented, “I am very excited to join the strong biotechnology team at ROTH, which has distinguished itself with industry leading coverage in NASH, oncology, and immunology. The recent emergence of new treatment modalities as well as genomic and diagnostic tools makes this a very exciting time in the biotechnology arena for patients, physicians, drug developers, and investors. I look forward to working with the rest of the ROTH biotechnology team to continue to provide high quality research with a focus on uncovering unrecognized value in future industry leaders and game changing therapeutics.”
“We are excited to have Jerry join our healthcare research team,” said Byron Roth, CEO of ROTH Capital Partners. “His addition further demonstrates our unwavering commitment to the life sciences sector. I’m confident that Jerry’s expertise in biotechnology will enhance our ability to continue to build upon our over ten-year track record of success in assisting both companies and investors in the healthcare sector.”
About Roth Capital Partners, LLC:
ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access.
Headquartered in Newport Beach, Calif., ROTH is privately-held and owned by its employees, and maintains offices throughout the U.S. For more information on ROTH, please visit www.roth.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181105005658/en/